Allergic Reactions After the Administration of COVID-19 Vaccines

Overview

Journal Front Public Health

Specialty Public Health

Date 2022 Jun 3

PMID 35655467

Authors

Sainan Bian

Lisha Li

Zixi Wang

Le Cui

Yingyang Xu

Kai Guan

Bin Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Data on allergic reactions after the administration of coronavirus disease (COVID-19) vaccines are limited. Our aim is to analyze reports of allergic reactions after COVID-19 vaccine administration.

Methods: The Vaccine Adverse Event Reporting System database was searched for reported allergic reactions after the administration of any of the COVID-19 vaccines from December 2020 to June 2021. After data mapping, the demographic and clinical characteristics of the reported cases were analyzed. Potential factors associated with anaphylaxis were evaluated using multivariable logistic regression models.

Results: In total, 14,611 cases were reported. Most cases of allergic reactions comprised women (84.6%) and occurred after the first dose of the vaccine (63.6%). Patients who experienced anaphylaxis were younger (mean age 45.11 ± 5.6 vs. 47.01 ± 6.3 years, < 0.001) and had a higher prevalence of a history of allergies, allergic rhinitis, asthma, and anaphylaxis than those who did not ( < 0.05). A history of allergies (odds ratio (OR) 1.632, 95% confidence interval (CI) 1.467-1.816, < 0.001), asthma (OR 1.908, 95%CI 1.677-2.172, < 0.001), and anaphylaxis (OR 7.164, 95%CI 3.504-14.646, < 0.001) were potential risk factors for anaphylaxis. Among the 8,232 patients with reported outcomes, 16 died.

Conclusions: Female predominance in allergic reaction cases after the receipt of COVID-19 vaccines was observed. Previous histories of allergies, asthma, or anaphylaxis were risk factors for anaphylaxis post-vaccination. People with these risk factors should be monitored more strictly after COVID-19 vaccination.

Citing Articles

Impact of Comorbidities and Skin Diseases on Post-Vaccination Reactions: A Study on COVID-19 Vaccinations in Poland.

Jeskowiak-Kossakowska I, Nowotarska P, Grosman-Dziewiszek P, Szelag A, Wiatrak B J Clin Med. 2024; 13(20).

PMID: 39458123 PMC: 11508506. DOI: 10.3390/jcm13206173.

The Ambivalence of Post COVID-19 Vaccination Responses in Humans.

Gopalaswamy R, Aravindhan V, Subbian S Biomolecules. 2024; 14(10).

PMID: 39456253 PMC: 11506738. DOI: 10.3390/biom14101320.

Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study.

Luxi N, Ciccimarra F, Bellitto C, Raethke M, van Hunsel F, Lieber T Vaccines (Basel). 2024; 12(9).

PMID: 39340089 PMC: 11435548. DOI: 10.3390/vaccines12091059.

RNA editing in response to COVID-19 vaccines: unveiling dynamic epigenetic regulation of host immunity.

Jin Y, Liang Y, Pan J, Huang W, Feng Y, Sui W Front Immunol. 2024; 15:1413704.

PMID: 39308856 PMC: 11413487. DOI: 10.3389/fimmu.2024.1413704.

Incidence and Outcomes of COVID-19 Vaccine Hypersensitivity Reactions and Success of COVID-19 Vaccine Provocation Tests Post Previous COVID-19 Vaccine Hypersensitivity.

Kurniawan A, Koesnoe S, Yunihastuti E, Shatri H Medicines (Basel). 2024; 11(6).

PMID: 38921599 PMC: 11205891. DOI: 10.3390/medicines11060012.

References

Shimabukuro T, Nguyen M, Martin D, DeStefano F . Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015; 33(36):4398-405. PMC: 4632204. DOI: 10.1016/j.vaccine.2015.07.035. View

. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021; 70(2):46-51. PMC: 7808711. DOI: 10.15585/mmwr.mm7002e1. View

Turner P, Ansotegui I, Campbell D, Cardona V, Ebisawa M, El-Gamal Y . COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021; 14(2):100517. PMC: 7857113. DOI: 10.1016/j.waojou.2021.100517. View

. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(4):125-129. PMC: 7842812. DOI: 10.15585/mmwr.mm7004e1. View

Dziedzic A, Riad A, Attia S, Klugar M, Tanasiewicz M . Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe. J Clin Med. 2021; 10(22). PMC: 8623766. DOI: 10.3390/jcm10225338. View

Sellaturay P, Nasser S, Ewan P . Polyethylene Glycol-Induced Systemic Allergic Reactions (Anaphylaxis). J Allergy Clin Immunol Pract. 2020; 9(2):670-675. DOI: 10.1016/j.jaip.2020.09.029. View

Stevens G, Alkema L, Black R, Boerma J, Collins G, Ezzati M . Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet. 2016; 388(10062):e19-e23. DOI: 10.1016/S0140-6736(16)30388-9. View

Rosenblum H, Gee J, Liu R, Marquez P, Zhang B, Strid P . Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet Infect Dis. 2022; 22(6):802-812. PMC: 8901181. DOI: 10.1016/S1473-3099(22)00054-8. View

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020; 21(2):181-192. PMC: 7832443. DOI: 10.1016/S1473-3099(20)30843-4. View

10.

Montano D . Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States. Front Public Health. 2022; 9:756633. PMC: 8850379. DOI: 10.3389/fpubh.2021.756633. View

11.

Riad A, Pokorna A, Attia S, Klugarova J, Koscik M, Klugar M . Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J Clin Med. 2021; 10(7). PMC: 8037149. DOI: 10.3390/jcm10071428. View

12.

Nilsson L, Brockow K, Alm J, Cardona V, Caubet J, Gomes E . Vaccination and allergy: EAACI position paper, practical aspects. Pediatr Allergy Immunol. 2017; 28(7):628-640. DOI: 10.1111/pai.12762. View

13.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

14.

Gee J, Marquez P, Su J, Calvert G, Liu R, Myers T . First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(8):283-288. PMC: 8344985. DOI: 10.15585/mmwr.mm7008e3. View

15.

McNeil M, DeStefano F . Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018; 141(2):463-472. PMC: 6602527. DOI: 10.1016/j.jaci.2017.12.971. View

16.

McNeil M, Weintraub E, Duffy J, Sukumaran L, Jacobsen S, Klein N . Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2015; 137(3):868-78. PMC: 4783279. DOI: 10.1016/j.jaci.2015.07.048. View

17.

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

18.

Zhou Z, Stone Jr C, Jakubovic B, Phillips E, Sussman G, Park J . Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. J Allergy Clin Immunol Pract. 2020; 9(4):1731-1733.e3. PMC: 8090930. DOI: 10.1016/j.jaip.2020.11.011. View

19.

Su J, Moro P, Ng C, Lewis P, Said M, Cano M . Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016. J Allergy Clin Immunol. 2019; 143(4):1465-1473. PMC: 6580415. DOI: 10.1016/j.jaci.2018.12.1003. View

20.

Ruggeberg J, Gold M, Bayas J, Blum M, Bonhoeffer J, Friedlander S . Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007; 25(31):5675-84. DOI: 10.1016/j.vaccine.2007.02.064. View